Compare PRT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | RNTX |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 38.9M |
| IPO Year | N/A | N/A |
| Metric | PRT | RNTX |
|---|---|---|
| Price | $3.87 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 28.0K | ★ 184.8K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $6,009,225.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.26 | $1.04 |
| 52 Week High | $4.63 | $3.50 |
| Indicator | PRT | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 58.01 |
| Support Level | $3.83 | $1.34 |
| Resistance Level | $3.95 | $1.58 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 8.33 | 87.50 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.